/RANI
RANI Stock - Rani Therapeutics Holdings, Inc.
Healthcare|BiotechnologyNASDAQ
$1.51-0.66%
$0.01 (-0.66%) • Dec 19
81
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
High Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.62
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+937.7%upside
Target: $15.67
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for RANI
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$1.49 – $1.53
TARGET (TP)$15.67
STOP LOSS$1.39
RISK/REWARD1:118.0
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.42
52W High$3.87
52W Low$0.39
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $1.03M | N/A | N/A | $2.72M | $462,000 |
| Gross Profit | $1.03M | $-822,000 | N/A | $2.72M | $462,000 |
| Gross Margin | 100.0% | N/A | N/A | 100.0% | 100.0% |
| Operating Income | $-53,314,000 | $-66,099,000 | $-63,451,000 | $-51,599,000 | $-16,544,000 |
| Net Income | $-30,018,000 | $-33,970,000 | $-30,588,000 | $-8,331,000 | $-16,703,000 |
| Net Margin | -2920.0% | N/A | N/A | -306.6% | -3615.4% |
| EPS | $-1.05 | $-1.33 | $-1.28 | $-0.42 | $-0.85 |
Company Overview
Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics. The company develops the RaniPill capsule, a platform that is intended to replace subcutaneous or IV injection of biologics with oral dosing. Its product pipeline includes RT-101, an octreotide, which has completed Phase I clinical trial for the treatment of neuroendocrine tumors and acromegaly; RT-105, an anti-TNF-alpha antibody to treat psoriatic arthritis; RT-102, a parathyroid hormone that is in preclinical studies for the treatment of osteoporosis; RT-109, a human growth hormone to treat growth hormone deficiency; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-106, a basal insulin for the treatment of type 2 diabetes. The company was incorporated in 2012 and is headquartered in San Jose, California.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
7
100%
Hold / Neutral
0%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
7 Bullish0 Neutral/Bearish
Price Targets
$19
Average Target
↑ 1139.4% Upside
Now
$10
Low
$19
Average
$28
High
Based on 7 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| August 2nd 2024 | Oppenheimer | Initiation | Outperform | $17 |
| June 14th 2024 | Maxim Group | Initiation | Buy | $15 |
| June 13th 2024 | Rodman & Renshaw | Initiation | Buy | $10 |
| April 17th 2023 | BTIG Research | Resumed | Buy | $24 |
| October 11th 2022 | UBS | Initiation | Buy | $15 |
| July 27th 2022 | H.C. Wainwright | Initiation | Buy | $22 |
| June 13th 2022 | Wedbush | Initiation | Outperform | $28 |
Earnings History & Surprises
RANIBeat Rate
56%
Last 18 quarters
Avg Surprise
+9.4%
EPS vs Estimate
Beats / Misses
10/6
2 met exactly
Latest EPS
$-0.12
Q4 2025
EPS Surprise History
Q1 24
+12.9%
$-0.27vs$-0.31
Q2 24
-26.1%
$-0.29vs$-0.23
Q3 24
+10.3%
$-0.26vs$-0.29
Q4 24
-9.1%
$-0.24vs$-0.22
Q1 25
-12.5%
$-0.27vs$-0.24
Q2 25
0.0%
$-0.22vs$-0.22
Q3 25
+5.3%
$-0.18vs$-0.19
Q4 25
-33.3%
$-0.12vs$-0.09
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 30, 2026 | $-0.03 | — | — | — |
Q4 2025 | Nov 6, 2025 | $-0.09 | $-0.12 | -33.3% | ✗ MISS |
Q3 2025 | Aug 7, 2025 | $-0.19 | $-0.18 | +5.3% | ✓ BEAT |
Q2 2025 | May 13, 2025 | $-0.22 | $-0.22 | 0.0% | = MET |
Q1 2025 | Mar 31, 2025 | $-0.24 | $-0.27 | -12.5% | ✗ MISS |
Q4 2024 | Nov 14, 2024 | $-0.22 | $-0.24 | -9.1% | ✗ MISS |
Q3 2024 | Aug 6, 2024 | $-0.29 | $-0.26 | +10.3% | ✓ BEAT |
Q2 2024 | May 6, 2024 | $-0.23 | $-0.29 | -26.1% | ✗ MISS |
Q1 2024 | Mar 20, 2024 | $-0.31 | $-0.27 | +12.9% | ✓ BEAT |
Q4 2023 | Nov 8, 2023 | $-0.47 | $-0.36 | +23.4% | ✓ BEAT |
Q3 2023 | Aug 11, 2023 | $-0.40 | $-0.37 | +7.5% | ✓ BEAT |
Q2 2023 | May 10, 2023 | $-0.47 | $-0.33 | +29.8% | ✓ BEAT |
Q1 2023 | Mar 22, 2023 | $-0.26 | $-0.35 | -34.6% | ✗ MISS |
Q4 2022 | Nov 10, 2022 | $-0.33 | $-0.33 | 0.0% | = MET |
Q3 2022 | Aug 10, 2022 | $-0.28 | $-0.31 | -10.7% | ✗ MISS |
Q2 2022 | May 11, 2022 | $-1.00 | $-0.29 | +71.0% | ✓ BEAT |
Q1 2022 | Mar 29, 2022 | $-1.28 | $-0.27 | +78.9% | ✓ BEAT |
Q4 2021 | Nov 15, 2021 | $-0.21 | $-0.16 | +23.8% | ✓ BEAT |
Q3 2021 | Sep 13, 2021 | $-0.18 | $-0.12 | +33.3% | ✓ BEAT |
Q3 2021 | Aug 2, 2021 | — | $-0.30 | — | — |
Latest News
Rani Therapeutics Hldgs Q3 EPS $(0.12) Beats $(0.15) Estimate
📈 PositiveBenzinga•Nov 6, 2025, 09:57 PM
HC Wainwright & Co. Assumes Rani Therapeutics Hldgs at Buy, Announces Price Target of $11
📈 PositiveBenzinga•Oct 21, 2025, 10:41 AM
Maxim Group Maintains Buy on Rani Therapeutics Hldgs, Raises Price Target to $10
📈 PositiveBenzinga•Oct 20, 2025, 04:11 PM
Rani Therapeutics Holdings shares are trading higher after the company on Friday announced a Collaboration and License Agreement with Chugai Pharmaceutical for the development and commercialization of an oral product. The company announced an oversubscribed $60.3 million private placement.
📈 PositiveBenzinga•Oct 20, 2025, 11:41 AM
Rani Therapeutics Shares Resume Trading
➖ NeutralBenzinga•Oct 17, 2025, 04:01 PM
Rani Therapeutics Shares Halted On Circuit Breaker To The Upside, Stock Now Up 369.31%
📈 PositiveBenzinga•Oct 17, 2025, 03:50 PM
Rani Therapeutics Shares Resume Trade
➖ NeutralBenzinga•Oct 17, 2025, 03:50 PM
Rani Therapeutics Shares Halted On Circuit Breaker To The Upside, Stock Now Up 337.46%
📈 PositiveBenzinga•Oct 17, 2025, 03:45 PM
Rani Therapeutics Shares Halted On Circuit Breaker To The Upside, Stock Now Up 261.01%
📈 PositiveBenzinga•Oct 17, 2025, 03:02 PM
Rani Therapeutics surges on Chugai licensing deal, private placement
📈 PositiveSeeking Alpha•Oct 17, 2025, 01:56 PM
Rani Therapeutics Holdings shares are trading higher after the company announced a Collaboration and License Agreement with Chugai Pharmaceutical for the development and commercialization of an oral product. The company announced an oversubscribed $60.3 million private placement.
📈 PositiveBenzinga•Oct 17, 2025, 01:09 PM
Rani Therapeutics Inks Up To $1.085B Chugai Collaboration For Oral Biologics; Announces Oversubscribed $60.3M Private Placement And $10M Upfront
📈 PositiveBenzinga•Oct 17, 2025, 11:31 AM
Rani Therapeutics announces $3M registered direct offering; shares down nearly 31%
📉 NegativeSeeking Alpha•Jul 15, 2025, 01:31 PM•Also:
Frequently Asked Questions about RANI
What is RANI's current stock price?
Rani Therapeutics Holdings, Inc. (RANI) is currently trading at $1.51 per share. The stock has moved -0.66% today.
What is the analyst price target for RANI?
The average analyst price target for RANI is $15.67, based on 1 analyst.
What sector is Rani Therapeutics Holdings, Inc. in?
Rani Therapeutics Holdings, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is RANI's market cap?
Rani Therapeutics Holdings, Inc. has a market capitalization of $0.11 billion, making it a small-cap company.
Does RANI pay dividends?
No, Rani Therapeutics Holdings, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorAPLT
Applied Therapeutics, Inc.
$0.13
Mkt Cap: $0.0B
CRBP
Corbus Pharmaceuticals Holdings, Inc.
$8.12
Mkt Cap: $0.1B
CRDF
Cardiff Oncology, Inc.
$2.57
Mkt Cap: $0.2B
CYBN
Cybin Inc.
$7.18
Mkt Cap: $0.4B
ELTX
Elicio Therapeutics, Inc.
$7.94
Mkt Cap: $0.1B
IPHA
Innate Pharma S.A.
$1.75
Mkt Cap: $0.1B
MIST
Milestone Pharmaceuticals Inc.
$2.15
Mkt Cap: $0.2B
MOLN
Molecular Partners AG
$4.39
Mkt Cap: $0.2B
SGMO
Sangamo Therapeutics, Inc.
$0.45
Mkt Cap: $0.2B
TNXP
Tonix Pharmaceuticals Holding Corp.
$17.09
Mkt Cap: $0.1B
Explore stocks similar to RANI for comparison